Anteris Technologies Global Corp. (AVR)
| Market Cap | 823.52M +468.1% |
| Revenue (ttm) | 2.24M -9.6% |
| Net Income | -103.56M |
| EPS | -1.62 |
| Shares Out | 97.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 568,651 |
| Open | 8.48 |
| Previous Close | 8.61 |
| Day's Range | 8.41 - 8.63 |
| 52-Week Range | 3.30 - 11.06 |
| Beta | 0.73 |
| Analysts | Strong Buy |
| Price Target | 15.33 (+81.42%) |
| Earnings Date | Aug 11, 2026 |
About AVR
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tiss... [Read more]
Financial Performance
In 2025, AVR's revenue was $1.91 million, a decrease of -29.23% compared to the previous year's $2.70 million. Losses were -$94.14 million, 23.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AVR stock is "Strong Buy." The 12-month stock price target is $15.33, which is an increase of 81.42% from the latest price.
News
Anteris to Present at September Healthcare Investor Conferences
MINNEAPOLIS and BRISBANE, Australia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to d...
Anteris Technologies Announces Results for the Second Quarter of 2026
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to d...
Anteris Technologies files to sell 5.39M shares of common stock
17:14 EDT Anteris Technologies (AVR) files to sell 5.39M shares of common stock
Anteris Technologies cleared by ANSM for DurAVR THV trial
Anteris Technologies (AVR) announced that it has received full regulatory clearance from the French National Agency for Medicines and Health Products Safety for the DurAVR Transcatheter Heart Valve gl...
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
MINNEAPOLIS and BRISBANE, Australia, June 08, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full ...
Anteris Technologies price target raised to $18 from $17 at Barclays
Barclays raised the firm’s price target on Anteris Technologies (AVR) to $18 from $17 and keeps an Overweight rating on the shares. The company’s Q1 results included an update on…
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
MINNEAPOLIS and BRISBANE, Australia, May 13, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed...
Anteris Announces Results for the First Quarter of 2026
MINNEAPOLIS and BRISBANE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed...
Anteris Technologies: First U.S. patients treated in global PARADIGM trial
Anteris Technologies (AVR) announced that the first patients in the United States have been enrolled and successfully treated in the DurAVR Transcatheter Heart Valve global pivotal trial for patients ...
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
MINNEAPOLIS and BRISBANE, Australia, May 05, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committe...
Anteris Technologies secures CMS reimbursement for trial site activation
Anteris Technologies (AVR) has secured U.S. Medicare reimbursement eligibility for the global pivotal PARADIGM Trial under a Centers for Medicare & Medicaid Services, or CMS, national coverage policy....
Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
MINNEAPOLIS and BRISBANE, Australia, April 28, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company commit...
Anteris Technologies assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage of Anteris Technologies (AVR) with an Overweight rating and $15 price target Anteris is positioned to capture meaningful share of the $12.4B transcatheter aortic val...
Anteris Technologies initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of Anteris Technologies (AVR) with an Overweight rating and $16 price target The firm believes the company’s DurAVR combines the best attributes of Edwards’ Sapien 3…
Anteris Reports 2025 Financial Results and Provides Corporate Update
MINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committ...
Anteris Technologies price target lowered to $17 from $22 at Barclays
Barclays lowered the firm’s price target on Anteris Technologies (AVR) to $17 from $22 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect…
Anteris Technologies price target lowered to $15 from $20 at Lake Street
Lake Street analyst Frank Takkinen lowered the firm’s price target on Anteris Technologies (AVR) to $15 from $20 and keeps a Buy rating on the shares. $320M in gross financing,…
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to...
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committ...
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committ...
Anteris Technologies announces $200M common stock offering
Anteris Technologies (AVR) announced that it is offering to sell, subject to market and other conditions, $200M of shares of its common stock through a proposed underwritten public offering. In…
Anteris Technologies files $500M mixed securities shelf
17:20 EST Anteris Technologies (AVR) files $500M mixed securities shelf
Anteris Technologies files to sell 9.1M shares of common stock for holders
16:36 EST Anteris Technologies (AVR) files to sell 9.1M shares of common stock for holders
Anteris Technologies Presents Data from 100 DurAVR(R) THV Patients at PCR London
Anteris Technologies (AVR) released 30-day clinical outcomes for the DurAVR THV in one hundred severe aortic stenosis patients with small aortic annuli – aortic annulus area 404 +/- 37mm2 -.
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
MINNEAPOLIS and BRISBANE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) today released 30-day clinical outcomes for th...